Actively Recruiting
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
Led by AbbVie · Updated on 2025-07-16
100
Participants Needed
13
Research Sites
235 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for intensive chemotherapy in Greece. Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled. Around 100 participants will be enrolled in the study in approximately 15 sites in Greece. Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 30 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 30 months.
CONDITIONS
Official Title
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Acute Myeloid Leukemia (AML) and ineligible for intensive chemotherapy
- Eligible to receive Venetoclax as a first-line therapy according to Greek Ministry of Health label
- Physician has decided to start Venetoclax treatment before enrolling in the study
You will not qualify if you...
- Participating in an interventional clinical trial within 30 days before starting Venetoclax treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Olympion General Clinic /ID# 268392
Pátrai, Achaia, Greece, 25443
Active, Not Recruiting
2
General Hospital of Athens Gennimatas /ID# 245968
Athens, Attica, Greece, 11527
Active, Not Recruiting
3
General Hospital of Athens Laiko /ID# 244338
Athens, Attica, Greece, 11527
Active, Not Recruiting
4
University General Hospital Attikon /ID# 248265
Athens, Attica, Greece, 12462
Active, Not Recruiting
5
University General Hospital of Heraklion PA.G.N.I /ID# 244337
Heraklion, Crete, Greece, 71500
Completed
6
General University Hospital of Alexandroupolis /ID# 244235
Alexandroupoli, Greece, 68100
Active, Not Recruiting
7
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 244339
Athens, Greece, 10676
Active, Not Recruiting
8
General Anti-cancer Hospital Agios Savvas /ID# 244408
Athens, Greece, 11522
Active, Not Recruiting
9
General Hospital of Athens Laiko - Hematology Location /ID# 244234
Athens, Greece, 11527
Active, Not Recruiting
10
University General Hospital of Ioannina /ID# 244336
Ioannina, Greece, 45500
Active, Not Recruiting
11
University General Hospital of Patras /ID# 244335
RION Patras Achaia, Greece, 26504
Completed
12
Papageorgiou General Hospital /ID# 248266
Thessaloniki, Greece, 56429
Actively Recruiting
13
General Hospital of Thessaloniki George Papanikolaou /ID# 244237
Thessaloniki, Greece, 57010
Active, Not Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here